News and Announcements
Issuance Of New Shares Pursuant To The DeClout Performance Share Plan
- Published July 16, 2015 3:12PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
July 10th 2015
The board of directors (the “Board”) of DeClout Limited (the “Company”) wishes to announce that, on 10 July 2015, the Company has allotted and issued an aggregate of 300,000 new ordinary shares in the capital of the Company (the “New Shares”), to an employee of the Company pursuant to the vesting of the share awards granted under the DeClout Performance Share Plan.
The New Shares rank pari passu in all respects with the existing shares of the Company. The New Shares are expected to be listed and quoted on Catalist on or around 14 July 2015, and trading of the New Shares is expected to commence with effect from 9.00 a.m. on the same date.
Following the allotment and issuance of the New Shares, the total number of issued and paid-up share capital of the Company has increased from 455,100,030 to 455,400,030 ordinary shares.
To read the full document, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
